Interferon: The Dawn of Recombinant Protein Drugs

J. Lindenmann, W.-D. Schleuning (Herausgeber)

Buch | Softcover

XIV, 138 Seiten

2013 | 1. Softcover reprint of the original 1st ed. 1999
Springer Berlin (Verlag)
978-3-662-03789-8 (ISBN)

Artikel merken

Forty years of Interferon I wish to dedicate this short introduction to the memory of Alick Isaacs (1921-1967), and to that of Sir Christopher Andrewes (1896-1988). Let us go back more than 40 years. In 1956 Isaacs was in charge of the Wodd Influenza Centre. Andrewes was head of the division of bac teriology and virology, and deputy director of the National Institute for Medical Research in London. When researchers are faced with a seemingly new phenomenon, ex planations are easy to come by. These explanations fall into two broad categories: the phenomenon in question is either due to something or to the lack of something. I apologize for the primitive way in which I ex press this, but I am going to give three examples, scattered over 100 years, of what I mean. First example: in 1880 the great French microbiologist Louis Pas teur was involved in work on chicken cholera. He was struck by the following observation: if a suitable chicken broth was inoculated with the bacterium, the organism grew profusely and the liquid became tur bid. If he now freed the fluid, by sedimentation or filtration, from the bulk of the organisms and re-inoculated it with the same bacterium, no growth occurred.

The publication ot the discovery of interferon by Issaacs and Lindenmann in 1957 was not only a milestone in the fields of virology, immunology and infectious diseases but also provided the seed for the growth of the biotechnology industry 20 years later. As of today the interferons belong to a small group of bestselling drugs of all times

1 Is There Life Without Interferon?.- 2 What Constitutes Therapeutic Success? The Interferons (1978-1998).- 3 The Prehistory and History of the Uses of Interleukin-2 in Cancer Therapy.- 4 Interferon-?: From Pass Interference to Cytokine Networking.- 5 A Biosemiotic View of Interferon: Toward a Biology of Really Living Organisms.- 6 The Clinical and Social Impact of Beta Interferon: the First Approved Therapy in Multiple Sclerosis.- 7 Closing Discussion.- Previous Volumes Published in this Series.

Erscheint lt. Verlag	3.10.2013
Reihe/Serie	Ernst Schering Foundation Symposium Proceedings
Reihe/Serie	Schering Foundation Symposium Proceedings Supplements
Zusatzinfo	XIV, 138 p. 2 illus.
Verlagsort	Berlin
Sprache	englisch
Maße	148 x 210 mm
Gewicht	212 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Medizin / Pharmazie ► Pharmazie
	Studium ► Querschnittsbereiche ► Infektiologie / Immunologie
	Technik ► Umwelttechnik / Biotechnologie
Schlagworte	Cancer • Cancer Therapy • Cytokine • cytokines • Interferon • Multiple Sclerosis • Protein • Protein Drugs • proteins
ISBN-10	3-662-03789-0 / 3662037890
ISBN-13	978-3-662-03789-8 / 9783662037898
Zustand	Neuware